Literature DB >> 32643006

[18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions.

Weipeng Huang1, Haojun Chen2, Bing Hao3, Xiurong Wu4, Yizhen Pang3, Long Sun3, Hua Wu3.   

Abstract

Entities:  

Year:  2020        PMID： 32643006     DOI： 10.1007/s00259-020-04941-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis.

Authors:  Yue Zhou; Xin Yang; Huipan Liu; Wenbin Luo; Hanxiang Liu; Taiyong Lv; Junzheng Wang; Jianhua Qin; Santao Ou; Yue Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-07       Impact factor: 9.236

2.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

3.  18F-FDG and 68 Ga-FAPI PET/CT for the evaluation of periprosthetic joint infection and aseptic loosening in rabbit models.

Authors:  Yiqun Wang; Yu Li; Liang Han; Xiaojun Zhang; Yong Huan; Jiahe Tian; Jun Wang; Cong Zhang; Erpeng Qi; Dongyun Zhang
Journal:  BMC Musculoskelet Disord       Date:  2022-06-20       Impact factor: 2.562

Review 4.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 5.  Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors:  Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

6.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

Review 7.  Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers.

Authors:  Stuart More; Mohlopheni J Marakalala; Michael Sathekge
Journal:  Front Med (Lausanne)       Date:  2021-12-10

8.  Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity - initial experience and comparison to [18F]FDG PET/CT and MRI.

Authors:  Christian Linz; Roman C Brands; Olivia Kertels; Alexander Dierks; Joachim Brumberg; Elena Gerhard-Hartmann; Stefan Hartmann; Andreas Schirbel; Sebastian Serfling; Yingjun Zhi; Andreas K Buck; Alexander Kübler; Julian Hohm; Constantin Lapa; Malte Kircher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-29       Impact factor: 9.236

9.  Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.

Authors:  Manuel Röhrich; Dominik Leitz; Frederik M Glatting; Annika K Wefers; Oliver Weinheimer; Paul Flechsig; Nicolas Kahn; Marcus A Mall; Frederik L Giesel; Clemens Kratochwil; Peter E Huber; Andreas von Deimling; Claus Peter Heußel; Hans Ulrich Kauczor; Michael Kreuter; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 11.082
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.